

DESIGN, SYNTHESIS AND PHARMACOLOGICAL EVALUATION NEW SERIES OF AZETIDINONE BASED PYRIMIDIN-2-ONE DERIVATIVES

Parth P. Patel^{*1}, Dharati D. Patel¹, Piyush J. Vyas² and Suresh C. Ameta³

¹Research Scholar of PAHER University, Udaipur, Rajasthan.

²Department of Chemistry, Sheth M. N. Science College, Patan, Gujarat

³Department of Chemistry, PAHER University, Udaipur, Rajasthan.

Article Received on
23 April 2022,

Revised on 13 May 2022,
Accepted on 03 June 2022

DOI: 10.20959/wjpr20228-24480

*Corresponding Author

Parth P. Patel

Research Scholar of PAHER
University, Udaipur,
Rajasthan.

ABSTRACT

Heterocyclic Compounds have so far been synthesized mainly due to the wide range of biological activities. Azetidinone plays an important role in biological field. From these reviews we synthesized a new series of 3-chloro-4-(3,4-dimethoxyphenyl)-1-{4-[6-(2-hydroxyphenyl)-2-oxo-1,2,5,6-tetrahydropyrimidin-4-yl]phenyl}azetidin-2-one derived from 3-chloro-4-(3,4-dimethoxyphenyl)-1-{4-[3-(substitutedphenyl)prop-2-enoyl]phenyl}-azetidin-2-one and urea using ethanol as a solvent. The title compounds were characterized by element analysis, and NMR spectral data. All the compounds were tested for their IR

antibacterial and antifungal activities by broth dilution method.

KEYWORDS: Azetidinone, IR, NMR, MTCC, broth dilution method.

INTRODUCTION

2-Azetidines have been extensively investigated by the organic chemists due to their close association with various types of biological activities.^[1] It is a four-membered cyclic lactam (β -lactam) skeleton has been recognized as a useful building block for the synthesis of large number of organic molecules by exploiting the strain energy associated with it. The Staudinger reaction ([2+2] ketene-imine cycloaddition reaction) is regarded as one of the most fundamental and versatile methods for the synthesis of structurally diverse 2-azetidinone derivatives. Azetidine-2-ones also have great importance because of the use of β -lactam derivatives as antibacterial agents recently, some other types of biological activity

beside the antibacterial activity have been reported in compounds containing 2-azetidinone ring. Such biological activities include antimicrobial, anti-tubercular, anti-inflammatory.^[2]

Heterocyclic compounds containing a pyrimidine fragment can be natural or synthetic analogues of nucleosides and nucleotides. They are of considerable interest due to a variety of their biological activities. The pyrimidine structural moiety is responsible for many kinds of biological activity, and is found in the molecules of natural compounds (guanidine, folic acid, etc.) as well as synthetic drugs (antitumor, antiviral, antibacterial drugs, etc.).^[3-10]

In the market, there are some approved, effective, well-known medicines containing pyrimidine moieties, such as antimicrobial agent Trimethoprim^[11], antiparkinsonian agent Piribedil^[12], and antiviral medication Aciclovir (Zovirax)^[13], etc. Currently, the interest in pyrimidin-containing biologically active compounds is still significant.^[14-16]

Experimental

All reagents were of analytical reagent grade and were used without further purification. All the product was synthesized and characterized by their spectral analysis. Melting points were taken in open capillary tube. The IR spectra were recorded on Bruker Model; Alpha, Laser Class1, made in Germany and Bruker instrument used for NMR Spectroscopy was 400 MHz and tetramethyl silane used as internal standard. Solvent used were DMSO. Purity of the compounds was checked by TLC on silica-G plates. All the compounds were tested for their antibacterial and antifungal activities by broth dilution method.

Preparation of 1-(4-acetylphenyl)-3-chloro-4-(3,4-dimethoxyphenyl)azetidin-2-one (1)

In a 100ml Round bottom flask 1-(4-[(3,4-dimethoxyphenyl)methylene]amino}phenyl)ethanone (0.01M) in 70ml benzene was taken. Chloro acetyl chloride (0.01M) was added at room temperature with constant stirring and triethylamine 1ml was added and the reaction mixture was refluxed for 7 hours. After the completion of reaction, solvent was removed by vacuum distillation. The solid was filtered, dried and recrystallized from toluene. The yield of the product was 68 % and the product melts at 105 °C. Found: C(63.40%) H(5.01%) N(3.86%), Calcd. for C₁₉H₁₈ClNO₄: C(63.42%) H(5.04%) N(3.89%). IR, cm⁻¹: (1) 3038 (=C-H), 2936 (-C-H stretching), 1730 (>C=O stretching), 1520 (>C=C< Aromatic), 1415 (-CH₃), 1290 (C-N), 1258 (C-O-C), 775 (C-Cl). ¹H-NMR (1- DMSO, δ, ppm): 2.516 (3H, s, -COCH₃), 3.343 (6H, s, -OCH₃), 4.820 (1H, s, >CH-Ar Azetidine), 5.485 (1H, s, >CH-Cl Azetidine), 6.610-7.898 (7H, m, Ar-H).

Preparation of 3-chloro-4-(3,4-dimethoxyphenyl)-1-{4-[3-(substitutedphenyl)prop-2-enoyl] phenyl}-azetidin-2-one (2a-2j)

To the solution of 1-(4-acetylphenyl)-3-chloro-4-(3,4-dimethoxyphenyl)azetidin-2-one (0.01M) in absolute ethanol (50 ml), aromatic aldehydes (0.01M) and 2% NaOH (10 ml) were added and refluxed for 10 hours. After refluxing the reaction mixture was concentrated, cooled, filtered and neutralized with dil. HCl. The solid residue thus obtained was crystallized by absolute ethanol. IR, cm^{-1} : (2i) 3069 ($=\text{C}-\text{H}$), 2904 ($-\text{C}-\text{H}$ stretching), 1702 ($>\text{C}=\text{O}$ stretching), 1514 ($>\text{C}=\text{C}<$ Aromatic), 1421 ($-\text{CH}_3$), 1314 ($\text{C}-\text{N}$), 1256 ($\text{C}-\text{O}-\text{C}$), 755 ($\text{C}-\text{Cl}$). $^1\text{H-NMR}$ (2g- $\text{C}_{27}\text{H}_{24}\text{ClNO}_6$ -DMSO, δ , ppm): 3.353 (9H, s, $-\text{OCH}_3$), 4.815 (1H, s, $>\text{CH}-\text{Ar}$ Azetidine), 5.482 (1H, s, $>\text{CH}-\text{Cl}$ Azetidine), 7.660 (2H, d, $-\text{CH}=\text{CH}-$ Chalcone), 9.118 (1H, s, $-\text{OH}$), 6.968-7.729 (10H, m, Ar-H).

Preparation of 3-chloro-4-(3,4-dimethoxyphenyl)-1-{4-[6-(substitutedphenyl)-2-oxo-1,2,5,6-tetrahydropyrimidin-4-yl]phenyl}azetidin-2-one (3a-3j)

A mixture of 3-chloro-4-(3,4-dimethoxyphenyl)-1-{4-[3-(substitutedphenyl)prop-2-enoyl]phenyl}-azetidin-2-one (0.01M), urea (0.01M) and 1gm. of potassium hydroxide (KOH) in 30 ml of ethanol was refluxed for 3 hours. After standing overnight the solid formed was collected and crystallized from acetone. IR, cm^{-1} : (3a) 3370 ($>\text{NH}-$), 3265 ($-\text{OH}$), 3078 ($=\text{C}-\text{H}$), 2971 ($-\text{C}-\text{H}$ stretching), 1720 ($>\text{C}=\text{O}$ stretching), 1596 ($>\text{C}=\text{N}$ stretching), 1513 ($>\text{C}=\text{C}<$ Aromatic), 1459 ($-\text{CH}_2$ bending), 1370 ($-\text{CH}_3$), 1336 ($\text{C}-\text{N}$), 1254 ($\text{C}-\text{O}-\text{C}$), 755 ($\text{C}-\text{Cl}$). $^1\text{H-NMR}$ (3d- $\text{C}_{27}\text{H}_{24}\text{ClN}_3\text{O}_5$ -DMSO, δ , ppm): 1.903 (2H, d, $-\text{CH}_2$ -Pyrimidine), 3.345 (6H, s, $-\text{OCH}_3$), 3.764 (1H, t, $-\text{CH}<$ Pyrimidine), 4.871 (1H, s, $>\text{CH}-\text{Ar}$ Azetidine), 5.448 (1H, s, $>\text{CH}-\text{Cl}$ Azetidine), 8.584 (1H, s, $-\text{NH}-$ Pyrimidine), 9.854 (1H, s, $-\text{OH}$), 6.628-7.927 (11H, m, Ar-H).

Reaction Scheme




Table 1: Physical constant of 3a-3j.

| Sr. No | Sub. No. | R | M.F. | Mol.Wt (g/m) | Yield % | M.P. °C | % Carbon | | % Hydrogen | | % Nitrogen | |
|--------|----------|-------------------------------------|---|--------------|---------|---------|----------|-------|------------|-------|------------|-------|
| | | | | | | | Found | Calcd | Found | Calcd | Found | Calcd |
| 1 | 3a | -2-OH | C ₂₇ H ₂₄ ClN ₃ O ₅ | 505.94 | 77 | 146 | 64.07 | 64.10 | 4.77 | 4.78 | 8.28 | 8.31 |
| 2 | 3b | -2-Cl | C ₂₇ H ₂₃ Cl ₂ N ₃ O ₄ | 524.39 | 72 | 140 | 61.81 | 61.84 | 4.40 | 4.42 | 7.95 | 8.01 |
| 3 | 3c | -4-Cl | C ₂₇ H ₂₃ Cl ₂ N ₃ O ₄ | 524.39 | 80 | 156 | 61.81 | 61.84 | 4.40 | 4.42 | 7.99 | 8.01 |
| 4 | 3d | -4-OH | C ₂₇ H ₂₄ ClN ₃ O ₅ | 505.94 | 85 | 159 | 64.07 | 64.10 | 4.75 | 4.78 | 8.30 | 8.31 |
| 5 | 3e | -H | C ₂₇ H ₂₄ ClN ₃ O ₄ | 489.95 | 73 | 147 | 66.16 | 66.19 | 4.93 | 4.94 | 8.57 | 8.58 |
| 6 | 3f | -3,4-OCH ₃ | C ₂₉ H ₂₈ ClN ₃ O ₆ | 550.00 | 78 | 162 | 63.32 | 63.33 | 5.10 | 5.13 | 7.60 | 7.64 |
| 7 | 3g | -4-OH-3-OCH ₃ | C ₂₈ H ₂₆ ClN ₃ O ₆ | 535.97 | 81 | 168 | 62.74 | 62.75 | 4.83 | 4.89 | 7.80 | 7.84 |
| 8 | 3h | -4-N(CH ₃) ₂ | C ₂₉ H ₂₉ ClN ₄ O ₄ | 533.02 | 83 | 153 | 65.31 | 65.35 | 5.46 | 5.48 | 10.47 | 10.51 |
| 9 | 3i | 4-OCH ₃ | C ₂₈ H ₂₆ ClN ₃ O ₅ | 519.98 | 74 | 158 | 64.66 | 64.68 | 5.01 | 5.04 | 8.05 | 8.08 |
| 10 | 3j | -3-NO ₂ | C ₂₇ H ₂₃ ClN ₄ O ₆ | 534.95 | 72 | 148 | 60.60 | 60.62 | 4.31 | 4.33 | 10.44 | 10.47 |

Table 2: Antimicrobial activities of 3a-3j.

| Sr. No. | Comp. No. | R | ANTIBACTERIAL ACTIVITY Minimal Inhibition Concentration(µg/ml) | | | | ANTIFUNGAL ACTIVITY Minimal Inhibition Concentration (µg/ml) | | |
|---------|-----------|-------------------------------------|---|---------------|--------------------|-------------|---|----------|-------------|
| | | | Gram - Ve bacteria | | Gram + Ve bacteria | | Fungus | | |
| | | | E. Coli | P. Aeruginosa | S. Aureus | S. Pyogenus | C. Albicans | A. Niger | A. Clavatus |
| | | | MTCC 443 | MTCC 1688 | MTCC 96 | MTCC 442 | MTCC 227 | MTCC 282 | MTCC 1323 |
| 1 | 3a | -2-OH | 500 | 500 | 500 | 250 | >1000 | 500 | 250 |
| 2 | 3b | -2-Cl | 500 | 500 | 500 | 500 | 1000 | 100 | 500 |
| 3 | 3c | -4-Cl | 1000 | 250 | 250 | 500 | 500 | 500 | 1000 |
| 4 | 3d | -4-OH | 500 | 500 | 500 | 500 | 250 | 500 | 100 |
| 5 | 3e | -H | 250 | 250 | 500 | 100 | >1000 | 250 | 250 |
| 6 | 3f | -3,4-OCH ₃ | 500 | 500 | 100 | 500 | 500 | 1000 | 500 |
| 7 | 3g | -4-OH-3-OCH ₃ | 1000 | 500 | 1000 | 250 | 500 | >1000 | 500 |
| 8 | 3h | -4-N(CH ₃) ₂ | 250 | 1000 | 500 | 250 | 250 | >1000 | >1000 |
| 9 | 3i | 4-OCH ₃ | 100 | 250 | 250 | 100 | 250 | 500 | 250 |
| 10 | 3j | -3-NO ₂ | 500 | 100 | 500 | 250 | 500 | 500 | 250 |

Table 3: The Standard Drugs minimum inhibition concentration.

| DRUG | E.COLI | P.AERUGINOSA | S.AUREUS | S.PYOGENUS |
|------------------|----------|--------------|----------|------------|
| - | MTCC 443 | MTCC 1688 | MTCC 96 | MTCC 442 |
| (MICROGRAMME/ML) | | | | |
| GENTAMYCIN | 0.05 | 1 | 0.25 | 0.5 |
| AMPICILLIN | 100 | -- | 250 | 100 |
| CHLORAMPHENICOL | 50 | 50 | 50 | 50 |
| CIPROFLOXACIN | 25 | 25 | 50 | 50 |
| NORFLOXACIN | 10 | 10 | 10 | 10 |

| DRUG | C.ALBICANS | A.NIGER | A.CLAVATUS |
|------------------|------------|----------|------------|
| - | MTCC 227 | MTCC 282 | MTCC 1323 |
| (MICROGRAMME/ML) | | | |
| NYSTATIN | 100 | 100 | 100 |
| GRESEOFULVIN | 500 | 100 | 100 |

CONCLUSION

The Main focus of this research work was to synthesize, characterize and evaluate antimicrobial activities of the newly synthesized Azetidinone based Pyrimidin-2-one derivatives, structures of synthesized compounds were confirmed and characterized with the help of analytical data's such as IR and ¹H-NMR. In summary, we have described the synthesis and antimicrobial activity of novel 3-chloro-4-(3,4-dimethoxyphenyl)-1-{4-[6-(substitutedphenyl)-2-oxo-1,2,5,6-tetrahydropyrimidin-4-yl]phenyl}azetidin-2-one. MIC values revealed that amongst newly synthesized compound having 2-chlorophenyl and 4-dimethylaminophenyl type linkage has shown good activity against the bacterial strains. Rest of all compounds exhibit moderate improvement in activity against some of the pathogenic strains.

ACKNOWLEDGEMENT

The authors are thankful to the Principal Dr. Piyush J. Vyas, Sheth M. N. Science College, Patan and Prof. Suresh C. Ameta department of chemistry Faculty of science Pacific academy of higher education and research university Udaipur for providing facilities for carrying out research work.

REFERENCES

1. Sharma, M.C., Sahu, N.K., Kohli, D.V., Chaturvedi, S.C., Sharma, S. (Synthesis, characterization and biological activities of some 1-(Nicotinylamino)-2 substituted azetidine-4-ones as potential antibacterial agents) *Digest Journal of Nanomaterial and Biostructures*, 2009; 4: 61.
2. Kumar, V., Jayadevalah, K.V., Nagaraja, T.S., Bharathi, D.R., Shameer, H., Jayachandaran, E., Sreenivasa G.M. (Synthesis, characterization and antimicrobial activity of new N-substituted -3-chloro-2-azetidinones) *Arch Pharma Sci & Res*, 2009; 1(1): 31.
3. Nital N. Patel and Pankaj S. Patel (Synthesis and characterization of Pyrimidine containing Thiazolidinone derivatives) *Indo American Journal of Pharmaceutical Research*, 2022; 12(01): 2291-2296.

4. Madhavan, G.R., Chakrabarti, R., Vikramadithyan, R.K., Mamidi, R.N.V.S., Balraju, V., Rajesh, B.M., Misra, P., Kumar, S.K.B., Lohray, B.B., Lohray, V.B., *et al.* (Synthesis and biological activity of novel pyrimidinone containing thiazolidinedione derivatives) *Bioorg. Med. Chem.*, 2002; 10: 2671–2680. [CrossRef]
5. Gangjee, A., Adaira, O., Queener, S.F. (Synthesis of 2,4-diamino-6-(thioarylmethyl)pyrido[2,3-d]pyrimidines as dihydrofolate reductase inhibitors) *Bioorg. Med. Chem.*, 2001; 9: 2929–2935. [CrossRef]
6. Saladino, R., Ciambecchini, U., Maga, G., Mastromarino, P., Conti, C., Botta, M. A. (new and efficient synthesis of substituted 6-[(2'-dialkylamino)ethyl]pyrimidine and 4-N,N-dialkyl-6-vinyl-cytosine derivative and evaluation of their anti-rubella activity) *Bioorg. Med. Chem.*, 2002; 10: 2143–2153. [CrossRef]
7. Skulnick, H.I., Weed, S.D., Eidson, E.E., Renis, H.E., Stringfellow, D.A., Wierenga, W. (Pyrimidinones 1,2-amino-5-halo-6-aryl-4(3H)-pyrimidinones. Interferon-Inducing antiviral agents) *J. Med. Chem.*, 1985; 28: 1864–1869. [CrossRef] [PubMed]
8. Dave, C.D. Shah, R.D. (Annellation of triazole and tetrazole systems onto pyrrolo[2,3-d]pyrimidines: Synthesis of tetrazolo[1,5-c]-pyrrolo[3,2-e]pyrimidines and triazolo[1,5-c]pyrrolo-[3,2-e]pyrimidines as potential antibacterial agents) *Molecules*, 2002; 7: 554–565. [CrossRef]
9. Zuniga, E.S., Korkegian, A., Mullen, S., Hembre, E.J., Ornstein, P.L., Cortez, G., Biswas, K., Naresh, K., Cramer, J., Masquelin, T., *et al.* (The synthesis and evaluation of triazolopyrimidines as anti-tubercular agents) *Bioorg. Med. Chem.*, 2017; 25: 3922–3946. [CrossRef] [PubMed]
10. Pretorius, S.I., Breytenbach, W.J., de Kock, C., Smith, P.J., N'Da, D.D. (Synthesis, characterization and antimalarial activity of quinolone-pyrimidine hybrids.) *Bioorg. Med. Chem.*, 2013; 21: 269–277. [CrossRef] [PubMed]
11. Brogden, R.N., Carmine, A.A., Heel, R.C., Speight, T.M., Avery, G.S. (Trimethoprim: A review of its antibacterial activity, pharmacokinetics and therapeutic use in urinary tract infections) *Drugs*, 1982; 23: 405–430. [CrossRef] [PubMed]
12. Millan, M.J., Cussac, D., Milligan, G., Carr, C., Audinot, V., Gobert, A., Lejeune, F., Rivet, J.M., Brocco, M., Duqueyroux, D., *et al.* (Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human 2-adrenoceptors Cellular and functional characterization.) *J. Pharmacol. Exp. Ther.*, 2001; 297: 876–887. [PubMed]

13. De Clercq, E., Field, H.J. (Antiviral prodrugs-The development of successful prodrug strategies for antiviral chemotherapy) *Br. J. Pharmacol*, 2006; 147: 1–11. [CrossRef] [PubMed]
14. Türkoğlu, E.A., Şentürk, M., Supuran, C.T., Ekinçi, D.(Carbonic anhydrase inhibitory properties of some uracil derivatives) *J. Enzyme Inhib. Med. Chem.*, 2017; 32: 74–77. [CrossRef] [PubMed]
15. Squarcialupi, L., Betti, M., Catarzi, D., Varano, F., Falsini, M., Ravani, A., Pasquini, S., Vincenzi, F., Salmaso, V., Sturlese, M., *et al.*(The role of 5-arylalkylamino- and 5-piperazino- moieties on the 7-aminopyrazolo[4,3-d]pyrimidine core in affecting adenosine A₁ and A_{2A} receptor affinity and selectivity profiles) *J. Enzyme Inhib. Med. Chem.*, 2017; 32: 248–263. [CrossRef] [PubMed]
16. Naguib, B.H., El-Nassan, H.B., Abdelghany, T.M. (Synthesis of new pyrido[2,3-b]pyrimidinone derivatives as Pim-1 inhibitors) *J. Enzyme Inhib. Med. Chem.*, 2017; 32: 457–467. [CrossRef] [PubMed]